Positive result

Understanding a positive result

A guide to understanding risk and taking action

Health. Illuminated.

Positive result

Understanding your Myriad MyRisk
hereditary cancer test result

Breast cancer RiskScore™

™

You may or may not see a breast cancer RiskScore and/or a Tyrer-Cuzick breast cancer risk assessment in thissection of the report. These results are calculated for
women who meet certain criteria and have never been
diagnosed with breast cancer themselves.

CONFIDENTIAL*54501233*
54501233

MyRisk Genetic Result

Name: Pt Last Name, Pt First Name

DOB: Dec 03, 1982

Accession #: 07007255-BLD

Report Date: Dec 03, 2021

Breast Cancer RiskScore®

Breast Cancer®
RiskScore :RESULT:

35.3%

35.3% Remaining Lifetime Breast Cancer Risk
1.7% 5-Year Breast Cancer Risk

Remaining Lifetime Breast Cancer Risk (Age-Adjusted)
GeneralPopulation

Your Myriad Genetics MyRisk Hereditary Cancer test has three main sections which
are summarized in the banner on the first page. Throughout the report, these
sections can be identified by the title on the top left of each page of the report.

0Your genetic result was POSITIVE.

This means that a clinically significant mutation, or harmful
genetic change, was found in one or more of the genes analyzed
as part of your testing. Since genes are passed down in families,
your close relatives, such as your children, brothers and sisters,parents, aunts and uncles, and cousins, are at risk to have thesame genetic change that was identified in you. It is important toshare your results with your relatives so they can discuss genetic
testing with their own healthcare providers.
If a variant of uncertain clinical significance (VUS) was identified,
it will also be listed in the genetic result section. A VUS is a
genetic change that may or may not be contributing to yourcancer risk. A VUS is not considered to be clinically actionable,
so medical care decisions should not be made based on a VUS.
We are committed to identifying information so that we canbetter understand these genetic changes. If new information isavailable about your specific VUS, that information will be sharedwith your healthcare provider.

10

15

20

25

30

35

40

45

50

®

BREAST CANCER RISKSCORE INTERPRETATIONThe breast cancer RiskScore provides an estimate of the remaining lifetime risk for breast cancer. A risk estimate at or above 20% is
associated with specific modified medical recommendations, including consideration of more aggressive breast cancer screening andadditional risk reduction measures. If applicable, details of these recommendations are provided in the accompanying MyRisk Medical
Management Tool or other supplemental material. Women with a risk estimate below 20% may still be appropriate for consideration ofmodified medical management based on other clinical factors or estimates from other breast cancer risk models, such as Tyrer-Cuzick,
Claus, and Gail.
TYRER-CUZICK BREAST CANCER RISK CALCULATIONClinical & cancer
family history information
2

3 Management tool

The MyRisk test looks at multiple genes associated withhereditary cancer risk. When a gene has a clinically significant
mutation, or harmful change, there is a higher chance for certain
cancers to develop. A list of the genes evaluated on your test
can be found in this section of your report. The gene table on our
website includes information about each gene and the cancers
with which it is associated.

5

REMAINING LIFETIME BREAST CANCER RISK: 18.5%

2 Clinical & cancer family history information

Genetic result

35.3%This Patient

1 Genetic result

1

20% Risk
Threshold

13.0%

The Clinical & Cancer Family History Information section
reviews the medical information that your healthcare
provider gave us about you and your family. Certain typesof cancer in the family or cancers diagnosed at early ages
can indicate that someone may have an elevated risk,even if no clinically significant mutations are found.
CONFIDENTIAL*54501230*
54501230

MyRiskTM Hereditary Cancer Test

MyRisk Genetic Result$

Test HCP, MD

Specimen Type: Blood

Test Medical Center

Draw Date:

Dec 03, 2021

Pt First Name

6609 BLANCO RD STE 200

Accession Date: Dec 03, 2021

Date of Birth: Dec 03, 1976

Report Date:

Patient ID:

SAN ANTONIO, TX 78216

Dec 03, 2021

Name:

Pt Last Name,

Patient id
FemaleAccession #:07007253-BLD(

Other clinical factors may influence individualized management. This analysis may be incomplete if details about
cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has aclinically significant mutation, the recommendations based on the clinical history analysis should be considered inlight of the possibility that this mutation explains all or some of the cancer history in the family.
MUTATION
Mutation Name
Heterozygous

INTERPRETATIONThis patient has Hereditary Breast and Ovarian Cancer
syndrome (HBOC).

<1B0A

6<;

The heterozygous germline BRCA2 mutation c.1163_1164dupTA is predicted to result in the premature truncation of the BRCA2 protein
at amino acid position 399 (p.Pro389Tyrfs*11).

This mutation is associated with increased cancer risk and should be regarded as clinically significant.
ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED
6;60.9All individuals carry DNA changes (i.e., variants), and most variants do not increase anindividual's risk of cancer or other diseases. When identified, variants of uncertain significance (VUS) are reported. Likely benign variants(Favor Polymorphisms) and benign variants (Polymorphisms) are not reported and available data indicate that these variants most likely do
not cause increased cancer risk. Present evidence does not suggest that non-clinically significant variant findings be used to modify patient
medical management beyond what is indicated by the personal and family history and any other clinically significant findings.
Myriad's myVisionTM Variant Classification Program performs ongoing evaluations of variant classifications. In certain*
cases, healthcare providers may be contacted for more clinical information or to arrange family testing to aid in variant classification. When
new evidence about a variant is identified and determined to result in clinical significance and management change, that information willautomatically be made available to the healthcare provider through an amended report.

® 2021 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615
The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad MyRisk,
RiskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and other jurisdictions.

Clinical & Cancer Family History Information$
Test HCP, MD

Specimen Type: Blood

Test Medical Center

Draw Date:

6609 BLANCO RD STE 200
SAN ANTONIO, TX 78216

MyRisk Genetic Result

Positive results with SINGLE SITE testing: If a member of your family
has tested positive for a clinically significant mutation, your provider
may have ordered testing for only that specific genetic change. Thisis known as single site testing. Your positive result means that you
DO carry the same harmful genetic change that was found in yourfamily member and you should discuss any changes to your medical
management that should be considered with your healthcare provider.
Since single site testing does not look for other genetic changes orassess additional risk from family history, this is not a comprehensive
risk assessment. Information in the management tool is specific ONLY
to the clinically significant mutation listed on your report.

3

Management tool

In this section of the result, there will be a table for each genein which a clinically significant mutation was identified. This
table outlines associated cancers and the risk to develop thesecancers. In another table, a summary of medical management
options from expert medical groups for these cancers and/or a list of other health problems associated with the mutation
are included. The medical management options may include
changes to screening frequency or recommendations for a
specific type of screening, discussions about preventive surgery,
consideration of preventive medication, and/or lifestyle changes.
In addition to the genetic result, the presence of certain cancers
in the family or certain medical findings in your own health history
can also influence your cancer risk. There may be additional
recommendations listed in this section due to these personalor family history health factors. If there are recommendations
for changes to your breast cancer screening based on your
RiskScore™ and/or a Tyrer-Cuzick breast cancer risk assessment,
they will be included in this section. Personal and family histories
can change over time, so it is important to keep your healthcare
providers up to date regarding any changes.

Name:

Pt Last Name,

Dec 03, 2021

Pt First Name

Accession Date: Dec 03, 2021

Date of Birth: Dec 03, 1976

® 2021 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615
The format and contents of this report are proprietaryand may
not be copied
or usedexceptfor purposesofPatient
ID:
Patient
id
ReportDate:
Dec03,without
2021 permission,
diagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad MyRisk,
RiskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of Myriad
Gender:FemaleGenetics, Inc. in the United States and other jurisdictions.

Accession #:MyRisk Genetic Result
Page 3 of 4

07007253-BLD

Requisition #: 90026822
PERSONAL / FAMILY CANCER HISTORY SUMMARY

Patient

None

Family History

None

PATIENT CLINICAL HISTORY SUMMARY
Woman's age

45

Ancestry

White/Non-Hispanic- HRT: Treatment TypeNot Specified

Hormone Replacement Therapy (HRT)- HRT: Current user

Not Specified

HeightNot Specified

WeightNot Specified- Number of years ago started

Age of menarche

Not Specified- Additional years of intended use

Patient's menopausal status

Not Specified

Daughters

Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with thepotential to alter medical intervention.

GENE

54501230

Not Specified

Not
SpecifiedSisters

Not
Specified

Not Specified

Not Specified
Not Specified- HRT: Past user

Not Specified

Age of first live birthRequisition #: 90026822

Gene NameCONFIDENTIAL*54501230*
MyRiskTM Hereditary Cancer Test

- Age of onset

Gender:

5-YEAR BREAST CANCER RISK: 0.8%

The National Comprehensive Cancer Network (NCCN) provides medical management recommendations for women with an estimatedremaining lifetime breast cancer risk greater than 20% based on Tyrer-Cuzick. These recommendations are summarized on the MyRisk
Management Tool (MMT). If an MMT is not included with this report, current management recommendations from the NCCN Breast
Cancer Screening and Diagnosis panel can be accessed at www.nccn.org. Version 7.02 of the Tyrer-Cuzick model was used for this risk
estimate. Tyrer-Cuzick model Versions 7.02 and 8.0 are available for download at the EMS-Trials website, http://www.ems-trials.org/
riskevaluator.

Not Specified- Number of years ago ended

Not Specified

Breast biopsy

Maternal
Aunts

Not Specified

Not
Specified

Paternal
Aunts

Not
Specified

CONFIDENTIAL*54501230*
54501230

MyRiskTM Hereditary Cancer Test

MyRisk Management Tool$

Test HCP, MD

Specimen Type: Blood

Test Medical Center

Draw Date:

6609 BLANCO RD STE 200
SAN ANTONIO, TX 78216

Name:

Pt Last Name,

Dec 03, 2021

Pt First Name

Accession Date: Dec 03, 2021

Date of Birth: Dec 03, 1976

® 2021 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615
The format and contents of this report are proprietaryand may
not be copied
used 2021
without permission,
exceptof id
Patient
ID:for purposes
Patient
ReportDate:
Decor 03,
diagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad MyRisk,
RiskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of Myriad
Gender:FemaleGenetics, Inc. in the United States and other jurisdictions.

Accession #:Clinical Information

07007253-BLD

Requisition #: 90026822(
Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with thepotential to alter medical intervention.

Other clinical factors may influence individualized management. This analysis may be incomplete if details about
cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has aclinically significant mutation, the recommendations based on the clinical history analysis should be considered inlight of the possibility that this mutation explains all or some of the cancer history in the family.
GENE

MUTATION

THIS GENETIC TEST RESULT IS ASSOCIATED WITH THE
FOLLOWING CANCER RISKS:

Gene Name

Mutation Name
Heterozygous

HIGH RISK: Breast, Ovarian, Pancreatic
ELEVATED RISK: Skin

Please see the Genetic Test Result for more details on any variant(s) detected in this patient, including variant classification information.
ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIEDTYRER-CUZICK BREAST CANCER RISK CALCULATIONThe Tyrer-Cuzick breast cancer risk estimate is only calculated for women who meet the following criteria: 1) age is younger than 85 years,2) no known mutation or inconclusive result has been found in the woman or any of her relatives, and 3) the sample was submitted with acurrent Test Request Form that includes all of the fields required to collect the information used in the calculation, and the provider has
not indicated on the Test Request Form that the Tyrer-Cuzick calculation is not appropriate for the patient. Version 7.02 of the TyrerCuzick model was used for this risk estimate. Tyrer-Cuzick model Versions 7.02 and 8.0 are available for download at the EMS-Trials
website, http://www.ems-trials.org/riskevaluator.

CLINICAL OVERVIEW OF GENETIC FINDINGS

Hereditary Breast and Ovarian Cancer syndrome (HBOC)• This patient has been found to have a mutation in the BRCA2 gene. Individuals with mutations in BRCA2 have Hereditary Breast andOvarian Cancer syndrome (HBOC).

• Women with HBOC have a risk for breast cancer that is greatly increased over the 12.5% lifetime risk for women in the general populationof the United States.
• Women with HBOC also have high risks for ovarian, fallopian tube, and primary peritoneal cancer.

® 2021 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615
The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad MyRisk,
RiskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and other jurisdictions.

MyRisk Management Tool

ResourcesYour healthcare provider is always your primary resource. You can findadditional information and educational material at www.mysupport360.com.
You can request a consultation with a genetic counselor at Myriad by going tomy.myriad.com/consults. During your consultation, the genetic counselor canhelp you understand your report and the implications of your results.
To view the full list of genes available on the MyRisk™ panel, please visit:www.myriadmyrisk.com/gene-table/

Next steps
Schedule any follow-up appointments and/or obtain referrals toappropriate specialists
Speak with your relatives about your results and encourage them to see
their healthcare provider about cancer prevention and genetic testing
Consider speaking with a clinical genetic counselor or other genetics
expert in your community about your test result and family history

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT
84108
myriad.com

Myriad, the Myriad logo, Myriad myRisk, the Myriad myRisk logo, riskScore
the riskScore logo, mySupport360, and the mySupport360 logo are either
trademarks or registered trademarks of Myriad Genetics, Inc. in the UnitedStates and other jurisdictions.
©2022, Myriad Genetic Laboratories, Inc.
MGMRHCPOSVPET / 02-22